A recent review on Nanoemulsion as a topical delivery system of antipsoriatic drugs
Psoriasis and psoriatic arthritis are a chronic skin disease of autoimmune system that is identified as patches of abnormal skin, affecting 2-5% of the world’s population. Psoriasis is an incurable lifetime disease which can be controlled and relieved through medication. Various approaches have been explored to treat the disease. Treatment of psoriasis includes topical therapy, systemic therapy and phototherapy. Topical therapy is the main psoriasis treatment. However, the conventional topical treatment such as gel and cream have low efficiency to poor cosmetic and aesthetic appeal leading to poor patient compliance or adherence. Nanoemulsions are transparent or translucent dispersions, having the droplet size less than 100 nm with ultra-low interfacial tension, large o/w interfacial areas and long term physical stability recently, much attention has been paid to the application of Nano emulsion as drug delivery system. A small droplet size would enhance the drug delivery and penetration of a drug through the psoriasis skin layer. A good selection of oils and surfactants would enhance the transdermal treatment efficacy in psoriatic patient.
Keywords: Nano emulsion topical drug delivery, psoriatic treatment
2. Wintereld L.S, Menter. A, Gordon. K and Gottlieb. A, Psoriasis treatment: current and emerging directed therapies, Ann. Rheum. Dis., 2005; 64:87–90.
3. Boehnck.W.H and Sch¨on. M. P, Animal models of psoriasis, Clin. Dermatol., 2007; 25(6):596–605.
4. Sampogna. F, Tabolli. S and Abeni. D, Living with psoriasis: prevalence of shame, anger, worry and problems in daily activities and social life, Acta Derm.-Venereol., 2012; 92:299–303.
5. Armstrong A. W., Schupp. C, Wu. J and Bebo. B, Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011, PLoS One, 2012; 7:e5293.
6. Weiss. S. C, Kimball. A. B, Liewehr. D. J, Blauvelt. A, Turner. M. L and Emanuel E. J., Quantifying the harmful effect of psoriasis in health-related quality of life, J. Am. Acad. Dermatol., 2002; 47:512–518.
7. Kimball. A. B., Gieler. U, Linder.D, Sampogna.F, Warren.R.B and Augustin.M, Psoriasis: is the important to a patient's life cumulative, J. Eur. Acad. Dermatol. Venereol., 2010: 24:989–1004.
8. Azfar R. S, Seminara. N. M, Shin D. B, Troxel. A. B, Margolis. D. J and Gelfand.J.M, Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis, Arch. Dermatol., 2012; 148:995–1000.
9. Wu.Y, Mills. D and Bala.M, Psoriasis: cardiovascular risk factors and other disease comorbidities, J. Drugs Dermatol., 2008; 7:373–377.
10. Gisondi. P and Girolomoni. G, Cardiometabolic comorbidities and the approach to patients with psoriasis, Actas Dermo-Siliogr., 2009: 100:14–21.
11. Paller AS., Mercy. K, Kwasny. MJ, Choon. SE, Cordoro. KM, Girolomoni. G, Menter. A, Tom. WL, Mahoney. AM, Oostveen. AM and Seyger.MMB, Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study, JAMA Dermatol., 2013; 149:166–176.
12. Augustin. M, Glaeske. G, Radtke. MA, Christophers. E, Reich . K and I. Sch¨afer, Epidemiology and comorbidity of psoriasis in children, Br. J. Dermatol., 2010, 162(3), 633–636.
13. Mitra. A and Wu Y, Topical delivery for the treatment of psoriasis, Expert Opin. Drug Delivery, 2010, 7(8), 977–992.
14. Rahman M, Akhter.S, Ahmad. J, Ahmad. MZ, Beg. S and Ahmad. FJ, Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy, Expert Opin. Drug Delivery, 2015, 12(4),635–652.
15. Warren. RB, Brown. BC and Griffiths. CEM , Topical treatments for scalp psoriasis, Drugs, 2008, 68(16), 2293–2302
16. Burroni. AG, Fassino. M, Tort. Ai and Visentin. E, How do disease perception, treatment features, and dermatologist–patient relationship impact on patientsassuming topical treatment? An Italian survey, Patient Related Outcome Measures, 2015, 6, 9.
17. Mooney.E, Rademaker. M, Dailey. R, . Daniel. BS, Drummond. C, Fischer .Gand Orchard.D, Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement, Australas. J. Dermatol., 2015; 56:241–251.
18. Lebwohl. M, Ting. PT and Koo. JYM , Psoriasis treatment: traditional therapy, Ann. Rheum. Dis., 2015, 64, 83–86.
19. Malik. IA , Akhter. S and Kamal.MA, Treatment of psoriasis by using Hijama: A case report, Saudi J. Biol. Sci., 2015; 22:117–121.
20. Georgiou.KR, Scherer.MA, Fan. CM, J. C. Cool, King TJ , Foster. BK and Xian. CJ, Methotrexate chemotherapy reduces osteogenesis but increases adipogenic potential in the bone marrow, J. Cell. Physiol., 2012; 227(3):909–918.
21. Rosenberg. P, Urwitz. H,.Johannesson. A, Ros. AM, Lindholm. J, Kinnman.N and Hultcrantz.R, Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment, J. Hepatol., 2007; 46:1111–1118.
22. Kawada.A, Evolution of targeted phototherapy for psoriasis, Expert Rev. Dermatol., 2013; 8(6):623–629.
23. Coven.TR, Burack.LH, Gilleaudeau.R, Keogh.M, Ozawa.M and Krueger.JG, Narrowband UV-B producessuperior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B, Arch. Dermatol., 1997, 133, 1514–1522.
24. Coven.TR, Walters.IB, Cardinale,I and . Krueger. JG, PUVA induced lymphocyte apoptosis: mechanism of action in psoriasis, Photodermatol., Photoimmunol. Photomed., 1999; 15:22–27.
25. Gorham.H, Treatment of psoriatic anthropathy by PUVA, Physiotherapy, 1980, 66, 40.
26. Chappe. SG, Roenigk. HH, Miller. AJ, Beeaff. DE and Tyrpin. L, The effect of photochemotherapy on the cardiovascular system, J. Am. Acad. Dermatol., 1981, 4, 561–566.
27. Rahman M, Alam K, Ahmad MZ, Classical to current approach for treatment of psoriasis: a review. Endocrine Metab Immune Disord Drug Targets. 2012; 12:287–302.
28. Bremmer S, Voorhees AS, Hsu S, Obesity and psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010; 63:1058–1069.
29. King Man H. Psoriasis. Hong Kong Med Diary 2010; 15:10-4.
30. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866-73.
31. Sutradhar, K.B. and L. Amin, Nanoemulsion: increasing possibilities drug delivery,European Journal of Nanomedicine,5(2), 2013, p. 97-110 .
32. Fernandez, P., et al., Nanoemulsion Formulation by emulsion phase inversion,Colloid and Surfaces A : Physiochemical and Engerinering Aspects, 2004; 251(1):53-58.
33. Gannu, R., et al., Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization ex vivo and in vivo characterization,International Journal of Pharmaceutics, 2010; 388(1-2): 231-241.
34. Zhao, Y., et al., Self-nanoemulfying drug delivery system (SNEDSS) for oral delivery Zeodary essential oil: formulation and bioavailability studies,International Journal of Pharmaceutics, 2010; 383(1):170-177.
35. Chen, H., et al., Hydrogel-thickened microemulsion for topical administration of drug molecule at an extremely low concentration,International Journal of Pharmaceutics, 2007; 341(1-2):8-84.
36. Cevc, G., Lipid vesicles and other colloids as drug carriers on the skin,Advanced Drug Delivery Reviews, 2004; 56(5): 675-711.
37. Bhaskar, K., et al., Lipid Nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex-vivo and in vivo studies, Lipids in Health and Disease, 8(6),2009.
38. Solans C, Esquena J, Forgiarini A, Morales D, Uson N, Izquierdo P., et al. Nanoemulsions: formation and properties. Surfactants in solution: fundamentals and applications, Surfactant Science Series, edited by: D. Shah, B. Moudgil, K.L. Mittal .Marcel Dekker, New York.2002; pp 525– 554.
39. Salim N, Ahmad N, Musa SH, Hashim R,. Tadrosc T F, Basriad M, Nanoemulsion as a topical delivery system of antipsoriatic drugs , Royal society of chemistry adv. 2016; 6:6234–6250 .
40. Singh R. Preparation of solid lipid nanoparticles through various methods using different precursors. Journal of Drug Delivery and Therapeutics, 2019; 9(2):415-419.
41. Majeed A., Bashir R., Farooq S., Maqboo, M, Preparation, Characterization and Applications of Nanoemulsions: An Insight. Journal of Drug Delivery and Therapeutics, 2019; 9(2):520-527
42. Norazlinaliza. S ,Noraini. A,Siti. HM, Rauzan. H, Tharwal FT . Mahiran B, Nanoemulsion as a topical delivery system of antipsoriatic drugs, Royal society of chemistry, 2016; 6:6234-6250.
43. Chellapa. P, Mohamed. AT, Keleb. EI, Elmahgoubi A, Eid. AM, Issa.YS, Elmarzugi. NA, Nanoemulsion and nanoemulgel as a topical formulation, IOSR journal of pharmacy, 2015; 5(10):43-47.
44. Dwivedi C, Tripath. A, Pradhan DK, Yadav R, Nanoemulsion systems: potential l approach for drug delivery, journal of drug delivery research, 2014; 3(2):11-30.
45. Khurana. B, Arora. D, Narang. RK, Topical delivery of nanoemulsion for antipsoriatic drugs, journal of drug delivery & therapeutics, 2018; 8(5):1-11.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).